Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Elan, a US-based neuroscience-based biotechnology company, and PPD, a global contract research organization, have formed a global business collaboration to deploy the expertise of both companies in a flexible, integrated manner.
Subscribe to our email newsletter
The idea is to expedite the execution of Elan‘s clinical programs on a global scale keeping in mind the advancement, progression and execution of Elan’s development portfolio.
PPD will now act as Elan’s primary service provider for all development functions and activities, while Elan will retain ownership of its assets and accountability for decision making related to strategy and progression of individual molecules and overall portfolio.
The collaboration will enable Elan to leverage the high quality capabilities of PPD across project and data management, biostatistics, regulatory, clinical and medical monitoring, quality assurance, and pharmacovigilance.
Elan executive vice president and head of Development and CMO Eliseo Salinas said the strategic collaboration with PPD will enable Elan to accelerate the progression of its science into the clinical development setting in a rapid and global fashion.
PPD CEO David Grange said the new relationship enables Elan to continually invest in and advance its world-leading work in biology and neuroscience, while leveraging PPD’s expertise and execution capabilities across key program areas on a global scale.